CompanyINKTNasdaqNew York, NY

MiNK Therapeutics

MiNK Therapeutics develops off-the-shelf allogeneic invariant natural killer T cell therapies for immune dysfunction.

SEC EDGAR ClinicalTrials.gov minktherapeutics.com

424B3Aug 17Latest SEC filing

Aug 13Latest story

August 2026

MiNK reports early Phase 2 data for agenT-797 in acute lung injury, Q2 2026 results

Aug 13Quarterly updateMiNK Therapeutics